Addex Therapeutics Ltd – Filings and Transcripts

NASDAQ: ADXN
Share price (6/2/26): $6.40
Market cap (6/2/26): $10.4 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

Late filing notification for annual report of foreign issuer

ended 12/31/24 FY 2024

Late filing notification for annual report of foreign issuer

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Shelf registration

Prospectus supplement

Updated info for already-effective prospectus

Prospectus supplement for primary offering

Ownership Filter

Lawton Vincent Michael

Teyssedou Lenaic Nathanael

Kalinichev Mikhail

Hill Raymond George

News Filter

Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness